Improving Diagnosis of Idiopathic Pulmonary Fibrosis
The newly launched Envisia Genomic Classifier aids in the molecular detection of Usual Interstitial Pneumonia (UIP), a hallmark of Idiopathic Pulmonary Fibrosis (IPF). The Envisia classifier may help reduce unnecessary diagnostic surgeries, patient anxiety and healthcare costs. Learn more.
Veracyte is pioneering the field of molecular cytology to improve patient outcomes and lower healthcare costs. More on our pipeline.
Veracyte Sees Clinical Evidence, Medicare Coverage as Major MDx Success Factors
(Sep 9, 2016, GenomeWeb)
Veracyte Achieves Major Medicare Coverage Milestone for the Percepta® Classifier to Improve Lung Cancer Diagnosis
(Sept 8, 2016)
New Data Show That Veracyte’s Afirma® Gene Expression Classifier Reduces Unnecessary Thyroid Surgeries and Costs During Long-Term Follow-Up
Additional Blues Plan Issues Positive Coverage Decision for the Afirma GEC; Two More Sign In-Network Contracts
(Dec 14, 2015)